Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial | MicrobiomeTrials
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2027-03-02Est. Completion: 2032-09-30
Enrollment target: 336 participants
Locations
Tower Cancer Research Foundation, Beverly Hills, California, United States
Cedars-Sinai Medical Center, Los Angeles, California, United States
Cedars-Sinai Cancer - Tarzana, Tarzana, California, United States
Torrance Memorial Physician Network - Cancer Care, Torrance, California, United States
Beebe South Coastal Health Campus, Millville, Delaware, United States
Helen F Graham Cancer Center, Newark, Delaware, United States
Medical Oncology Hematology Consultants PA, Newark, Delaware, United States
Beebe Health Campus, Rehoboth Beach, Delaware, United States
Kootenai Health - Coeur d'Alene, Coeur d'Alene, Idaho, United States
Kootenai Clinic Cancer Services - Post Falls, Post Falls, Idaho, United States
Kootenai Clinic Cancer Services - Sandpoint, Sandpoint, Idaho, United States
Illinois CancerCare-Bloomington, Bloomington, Illinois, United States
Illinois CancerCare-Canton, Canton, Illinois, United States
Illinois CancerCare-Carthage, Carthage, Illinois, United States
Carle at The Riverfront, Danville, Illinois, United States
Other microbiome trials you might be interested in